Printer Friendly

Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte, Olmesartan Medoxomil Combination for Hypertension Treatment.

Tokyo, Japan, Nov 30, 2006 - (JCN) - Daiichi Sankyo announced November 29 that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for a fixed dose combination of two antihypertensives, the calcium channel blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or Benicar.

Pending approval, the combination will be indicated for the treatment of hypertension and may be used either alone or in combination with other antihypertensive agents.

In a clinical trial, the amlodipine/olmesartan combination demonstrated clinically significant mean blood pressure reductions. It utilizes two complementary mechanisms of action, calcium channel blockade and angiotensin II receptor blockade.

Benicar, Daiichi Sankyo's currently marketed ARB, is the fastest growing medication in the fastest growing class of blood pressure-lowering drugs. Norvasc is the most widely used CCB on the market.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Dec 7, 2006
Previous Article:Asahi Glass Increases Fluon ETFE Fluoropolymer Production Capacity.
Next Article:Toray Files New Drug Application of TRK-820 Antipruritic Agent, Treatment of Severe Pruritus in Hemodialysis Patients in Japan.

Related Articles
Sankyo Announces Completion of Subject Registration for ORIENT Clinical Trial.
Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate.
Daiichi Pharmaceutical and Celestar Lexico-Sciences Completes Joint Research on Genome Drug.
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Daiichi Sankyo Now Authorized to Market Its Products in China.
Sankyo to Manufacture, Distribute Olmetic Antihypertensive Drug in China.
Fujifilm Acquires Daiichi Radioisotope Laboratories, Diagnostic Radiopharmaceuticals Manufacturer.
Daiichi Sankyo Subsidiary Applies for Additional Indication for Fentanyl Injection.
Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of Daiichi Pharmaceutical.
Sanko Lifetech Transfers Animal Health Products Business to Novartis Animal Health.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |